全文获取类型
收费全文 | 5797篇 |
免费 | 354篇 |
国内免费 | 118篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 52篇 |
妇产科学 | 20篇 |
基础医学 | 241篇 |
口腔科学 | 36篇 |
临床医学 | 1131篇 |
内科学 | 692篇 |
皮肤病学 | 27篇 |
神经病学 | 100篇 |
特种医学 | 124篇 |
外科学 | 1141篇 |
综合类 | 1250篇 |
预防医学 | 618篇 |
眼科学 | 14篇 |
药学 | 466篇 |
15篇 | |
中国医学 | 166篇 |
肿瘤学 | 170篇 |
出版年
2024年 | 7篇 |
2023年 | 120篇 |
2022年 | 144篇 |
2021年 | 323篇 |
2020年 | 283篇 |
2019年 | 174篇 |
2018年 | 147篇 |
2017年 | 202篇 |
2016年 | 254篇 |
2015年 | 242篇 |
2014年 | 514篇 |
2013年 | 666篇 |
2012年 | 414篇 |
2011年 | 434篇 |
2010年 | 339篇 |
2009年 | 265篇 |
2008年 | 239篇 |
2007年 | 219篇 |
2006年 | 170篇 |
2005年 | 145篇 |
2004年 | 124篇 |
2003年 | 115篇 |
2002年 | 96篇 |
2001年 | 98篇 |
2000年 | 77篇 |
1999年 | 60篇 |
1998年 | 48篇 |
1997年 | 46篇 |
1996年 | 22篇 |
1995年 | 29篇 |
1994年 | 21篇 |
1993年 | 32篇 |
1992年 | 15篇 |
1991年 | 12篇 |
1990年 | 12篇 |
1989年 | 8篇 |
1988年 | 12篇 |
1987年 | 5篇 |
1986年 | 11篇 |
1985年 | 20篇 |
1984年 | 10篇 |
1983年 | 13篇 |
1982年 | 19篇 |
1981年 | 6篇 |
1980年 | 12篇 |
1979年 | 14篇 |
1978年 | 18篇 |
1977年 | 4篇 |
1975年 | 2篇 |
1973年 | 3篇 |
排序方式: 共有6269条查询结果,搜索用时 250 毫秒
1.
目的探讨维持性血液透析(MHD)患者血清维生素D水平对下肢肌力减退的预测作用。 方法横断面研究设计,选择2018年9月至10月于战略支援部队特色医学中心血液净化中心的95例MHD患者,检测其血清25-羟维生素D3[25(OH)D3]水平,采用5次站立-坐下实验(5-STS)评价其下肢肌力。根据5-STS完成时间将MHD患者分为下肢肌力正常组(n=85)与减退组(n=10),比较两组患者人口学特征、实验室指标。采用多因素Logistic回归分析下肢肌力减退的影响因素,绘制受试者工作特征(ROC)曲线分析上述因素预测MHD患者发生下肢肌力减退的特异度和敏感度。 结果95例MHD患者血清25(OH)D3水平为11.00~99.50 nmol/L,中位数31.23(19.90~43.30)nmol/L;5-STS完成时间为3.55 s~18.71 s,中位数9.81(7.12,12.43)s,下肢肌力减退者10例(10.53%)。多因素Logistic回归分析显示,血清25(OH)D3是MHD患者下肢肌力减退的保护性因素[OR=0.761,95%CI(0.592~0.978),P=0.033]。进一步ROC曲线分析显示,25(OH)D3对应的ROC曲线下面积为0.815,其预测MHD患者发生下肢肌力减退的敏感度为80.00%,特异度为80.00%。 结论MHD患者血清25(OH)D3水平普遍较低,下肢肌力减退者更为明显;血清维生素D水平对MHD患者是否存在下肢肌力减退具有较好的预测价值。 相似文献
2.
Motofumi Maruta Takanori Miyoshi Naomi Matsuo Takuya Yamashina Kenji Irie Minako Tsuruta 《Journal of chemotherapy (Florence, Italy)》2021,33(1):51-55
We administered FOLFOX (oxaliplatin (L-OHP) plus infusional 5-fluorouracil (5-FU) and leucovorin) to an hemodialysis (HD) patient with advanced gastric cancer (AGC), and investigated pharmacokinetics (PKs) and dialyzability of L-OHP. The patient was a 54-year-old Japanese man with a diagnosis of inoperable AGC. FOLFOX was instituted 3?h prior to the start of a 4?h HD period with the L-OHP and 5-FU doses reduced by 50% for the first cycle, and 30% reduced dose was administered for the second cycle. We performed an analysis of the PKs of L-OHP during these two cycles. Volume of distribution and area under the curve of the 30% reduced L-OHP dose were 56.7?L and 30.0?μg·h/mL, respectively. A dose reduction of L-OHP by 30%?50% may be advisable for the initial administration, given the need for careful administration of chemotherapy in HD patients, with particular attention to the development of hematological toxicities and neuropathy. 相似文献
3.
目的:探讨园艺互动干预应用于维持性血液透析病人中的效果。方法:选择本院收治的行维持性血液透析病人157例,按照入院时间先后顺序分为对照组77例,观察组80例。对照组实施常规干预,观察组实施园艺互动干预。对比两组干预前后心理状态、应对方式、生活质量及总体幸福感变化。结果:观察组干预12周后症状自评量表(SCL-90)各维度评分低于对照组(P<0.05);观察组干预12周后积极应对评分高于对照组,消极应对评分低于对照组(P<0.05);观察组生活质量各维度评分高于对照组(P<0.05);观察组总体幸福感评分高于对照组(P<0.05)。结论:园艺互动干预应用于维持性血液透析病人可改善心理状态及应对方式,提升生活质量与总体幸福感。 相似文献
4.
ObjectiveThis meta-analysis investigated the effectiveness of PARP inhibitors (PARPis) as maintenance treatment in platinum sensitive recurrent ovarian cancer (ROC), stratifying results based on BRCA mutational status into five different categories: whole population, germ-line BRCA mutated patients, somatic BRCA mutated patients, HRD patients and wild type population.MethodsPubMed, Medline, Scopus, EMBASE and clinicaltrials.gov, as well as meeting proceedings were searched for eligible studies that described RCTs testing the efficacy of PARPis as maintenance treatment in platinum sensitive ROC. Data were extracted independently and analysed using RevMan statistical software version 5.3. Primary end-point was progression free survival (PFS).ResultsThe analysis confirmed the positive effect of PARPis in patients with platinum sensitive ROC in case of germinal or somatic BRCA mutations. Specifically, HR for PFS was 0.26, 95% CI 0.21–0.31, p < 0.00001 for the mutation of BRCA gene and 0.24, 95%, CI 0.12–0.48, p < 0.0001 for the somatic alteration. In addition, in the HRD population, studies that analysed the efficacy of PARPis reported a PFS improvement with HR 0.34, 95% CI 0.26–0.43, p < 0.00001. Finally, our analysis confirms the role of these drugs in prolonging PFS in the whole population with HR 0.36, 95% CI 0.32–0.42, p < 0.00001, although to a lesser extent, with a significant improvement even in wild type cancers with HR 0.49, 95%, CI 0.41–0.59, p < 0.00001).ConclusionsPARPis are effective regardless of BRCA mutational status. Future investigations are necessary to explore the use of different PARPis as monotherapy, comparing them among each other in terms of efficacy and toxicity, and exploring their potential re-use. 相似文献
5.
Ahmed M. Harraz Magdy El-Shabrawy Ahmed R. El-Nahas Hamdy El-Kappany Yasser Osman 《Clinical genitourinary cancer》2019,17(6):e1108-e1115
IntroductionThe objective of this study was to determine the efficiency of 1-year maintenance intravesical chemotherapy (MIC) in reducing bladder recurrence (BR) after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma compared with single intravesical instillation (SIC).Patients and MethodsBetween January 2015 and May 2017, patients who underwent RNU were randomized to receive SIC (epirubicin 50 mg) or MIC (once weekly for 6 weeks plus once monthly for 1 year). The primary outcome was the rate of histologically proven BR. The secondary outcomes included chemotherapy-related toxicities and disease-specific survival (DSS). Thirty-five patients in each arm were required to achieve a power of 80%.ResultsA total of 38 (SIC) and 36 (MIC) patients were analyzed. In SIC, BR developed in 5 (13.2%) over a median follow-up of 3 months (range, 3-6 months) compared with 9 (25%) patients over 12 months (range, 3-28 months) in MIC (P = .08). The 6- and 12-month BR-free survivals were the same (86.8%) in SIC versus 88.9% and 83.3% in MIC, respectively (P = .2). Lymphovascular invasion was significantly associated with BR (P = .04). Post-RNU intravesical chemotherapy regimens did not alter DSS. Blood transfusion and advanced tumor stage were independent predictors for DSS. No significant medication toxicity was reported.ConclusionsFollowing RNU, MIC did not change the natural course of BR beyond a single instillation apart from potentially delaying its occurrence. Lymphovascular invasion and blood transfusion were associated with worse BR and DSS outcomes, respectively. 相似文献
6.
7.
8.
9.
10.
目的:观察量化体育锻炼对维持性血液透析(MHD)患者的应用效果,探讨临床治疗体会。方法:将64例MHD患者随机分成2组各32例,对照组给予常规健康宣教、干预治疗和自主锻炼,观察组在其基础上给予量化体育锻炼干预治疗;观察2组患者的运动量指标变化情况,比较生活质量和疾病转归等相关指标。结果:干预6个月后,2组的上肢锻炼时间和步行运动量均较干预前明显提高(P0.01,0.05),观察组的提高幅度更高于对照组(P0.01);2组的疲乏状态、日常生活活动能力(ADL)、焦虑自评量表(SAS)和睡眠质量评分量表(SPIEGEL)等指标均较干预前明显降低(均P0.05),改良SGA评分明显提高(P0.01,0.05),观察组的改善幅度更高于对照组(P0.01)。治疗后,观察组的内瘘血管良好率和肾功能平稳率高于对照组(均P0.05),并发症率和再入院率降低(P0.05)。结论:对MHD患者给予量化体育锻炼干预治疗,能显著提高康复锻炼的运动量和优化锻炼效果,提高患者的生活质量,改善疾病预后。 相似文献